Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.

ABSTRACT:

Background

The Omicron (B.1.1.529) SARS-COV-2 variant has raised serious concerns because of its unprecedented rapid rate of spreading and the fact that there are 36 mutations in the spike protein. Since the vaccine-induced neutralizing antibody targets are the spike protein, this may lead to the possibility of vaccine-induced humoral immunity escape.

Methods

We measured the neutralizing activity in vitro for Omicron and compared this with wild type (WH-09) and Delta variants in human and monkey sera from different types of immunity. The monkey sera samples were collected at 1 and 3 months post three-dose inactivated (PiCoVacc) and recombinant protein (ZF2001) vaccination. Human sera were collected from 1 month post three-dose inactivated vaccination.

Results

In inact

SUBMITTER: Lv Q 

PROVIDER: S-EPMC8879626 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature